Anzeige
Mehr »
Login
Dienstag, 23.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Breaking News: InnoCan startet in eine neue Ära – FDA Zulassung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JGDZ | ISIN: US03969F1093 | Ticker-Symbol:
NASDAQ
22.04.24
15:30 Uhr
14,750 US-Dollar
+0,140
+0,96 %
1-Jahres-Chart
ARCUS BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
ARCUS BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur ARCUS BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
25.03.Navigating 5 Analyst Ratings For Arcus Biosciences2
20.03.Arcus Biosciences COO sells over $240k in company stock5
22.02.Earnings call: Arcus Biosciences reports strong Q4 results, plans for 20256
22.02.Arcus Biosciences GAAP EPS of -$1.08 misses by $0.06, revenue of $31M beats by $2.7M2
21.02.Arcus Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
21.02.Arcus Biosciences, Inc. - 10-K, Annual Report1
21.02.Arcus Biosciences, Inc. - 8-K, Current Report1
21.02.Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update143HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies...
► Artikel lesen
20.02.Arcus Biosciences Q4 2023 Earnings Preview2
19.02.Zimberelimab by Arcus Biosciences for Metastatic Colorectal Cancer: Likelihood of Approval2
19.02.Zimberelimab by Arcus Biosciences for Extrahepatic Bile Duct Cancer: Likelihood of Approval2
19.02.Zimberelimab by Arcus Biosciences for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval5
30.01.Arcus Biosciences: Did Gilead Sciences overpay for its latest investment?13
30.01.CLS, CGEN and RCUS are among pre market gainers5
30.01.Arcus Biosciences, Inc. - 8-K, Current Report1
30.01.US STOCKS Super Micro Computer, Arcus Biosciences, Agape ATP7
30.01.Pharma Giant Gilead Raises Stake In Cancer-Focused Arcus Biosciences, Stock Soars6
30.01.Arcus Biosciences surges after Gilead Sciences raises stake5
30.01.Gilead and Arcus Biosciences expand oncology partnership deal4
30.01.Gilead Sciences Increases Stake In Arcus Biosciences To 33%488 FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) has raised its stake in Arcus Biosciences Inc. (RCUS) to 33% to accelerate growth of their joint development programs that span multiple indications...
► Artikel lesen
Seite:  Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1